Context: For many patients, adhering to postmenopausal osteoporosis treatment is a challenge. Higher treatment satisfaction is associated with greater persistence with these therapies, which is associated with better outcomes. Objective: To evaluate the change in treatment satisfaction in postmenopausal women who were suboptimally adherent to daily or weekly oral bisphosphonates and who transitioned to denosumab versus a monthly oral bisphosphonate Design: Pooled data from two international, multicenter, randomized, open-label studies Setting: Outpatient clinical setting Patients: 1703 postmenopausal women aged >/=55 years with low bone mineral density who were suboptimally adherent with prior oral bisphosphonate therapy, as assessed by the Osteoporosis-Specific Morisky Medication Adherence Scale Interventions: Denosumab, a fully human monoclonal antibody to RANKL, 60 mg subcutaneously every 6 months versus the oral bisphosphonates ibandronate or risedronate 150 mg once monthly for 12 months Main Outcome Measures: Change in treatment satisfaction scores from baseline to months 6 and 12 using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is a validated tool that measures perception of four domains of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction. Results: Patients in both treatment groups showed improvement from baseline for all four TSQM domains at 6 and 12 months. However, the denosumab group had significantly (all P<0.001) greater improvements among all four TSQM domains at 6 and 12 months compared with the oral bisphosphonate group. Conclusions: Women with low adherence to oral bisphosphonates reported greater treatment satisfaction when transitioned to denosumab versus switching to a monthly oral bisphosphonate.
- ALENDRONATE THERAPY
- FRACTURE RATES